Pulmonx Positioned for Sustained Growth with Strong Q1 Performance and Strategic Initiatives

Analyst John Young CFA from Canaccord Genuity maintained a Buy rating on Pulmonx (LUNG – Research Report) and decreased the price target to $15.00 from $16.00.

John Young CFA has given his Buy rating due to a combination of factors that highlight Pulmonx’s strong performance and future growth potential. The company reported a solid first quarter with revenue slightly exceeding expectations and demonstrating better-than-expected SG&A leverage. Despite a slight miss in US revenue, the company anticipates a growth inflection in the second half of the year, driven by strategic initiatives.
Moreover, Pulmonx has reiterated its confidence in achieving long-term growth of over 20%, supported by its current valuation and ongoing efforts to expand its customer base and product offerings. The company’s guidance for 2025 remains strong, with expected revenue growth and stable gross margins. These factors, combined with the company’s proactive measures to mitigate potential tariff impacts, reinforce the Buy rating as Pulmonx is well-positioned for sustained growth.

In another report released today, Piper Sandler also reiterated a Buy rating on the stock with a $9.00 price target.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LUNG in relation to earlier this year.